We have previously shown that HAT1 was overexpressed in pancreatic cancer and that HAT1 silencing reduced the expression of PD-L1 on the surface of pancreatic cancer cells in a BRD4-dependent manner, improve the therapeutic efficacy of immune checkpoint blockade [38]. Here, HAT1 is linked to familial pancreatic carcinoma.